184 related articles for article (PubMed ID: 23033511)
1. Herpes simplex virus and HIV: genital infection synergy and novel approaches to dual prevention.
Thurman AR; Doncel GF
Int J STD AIDS; 2012 Sep; 23(9):613-9. PubMed ID: 23033511
[TBL] [Abstract][Full Text] [Related]
2. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection.
Celum CL; Robinson NJ; Cohen MS
J Infect Dis; 2005 Feb; 191 Suppl 1():S107-14. PubMed ID: 15627220
[TBL] [Abstract][Full Text] [Related]
3. An update on short-course episodic and prevention therapies for herpes genitalis.
Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L
Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886
[TBL] [Abstract][Full Text] [Related]
4. Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
Corey L; Wald A; Patel R; Sacks SL; Tyring SK; Warren T; Douglas JM; Paavonen J; Morrow RA; Beutner KR; Stratchounsky LS; Mertz G; Keene ON; Watson HA; Tait D; Vargas-Cortes M;
N Engl J Med; 2004 Jan; 350(1):11-20. PubMed ID: 14702423
[TBL] [Abstract][Full Text] [Related]
5. Topical microbicides for the prevention of genital herpes infection.
Keller MJ; Tuyama A; Carlucci MJ; Herold BC
J Antimicrob Chemother; 2005 Apr; 55(4):420-3. PubMed ID: 15743896
[TBL] [Abstract][Full Text] [Related]
6. HSV shedding.
Sacks SL; Griffiths PD; Corey L; Cohen C; Cunningham A; Dusheiko GM; Self S; Spruance S; Stanberry LR; Wald A; Whitley RJ
Antiviral Res; 2004 Aug; 63 Suppl 1():S19-26. PubMed ID: 15450382
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.
Vickerman P; Devine A; Foss AM; Delany-Moretlwe S; Mayaud P; Meyer-Rath G
Sex Transm Dis; 2011 May; 38(5):401-9. PubMed ID: 21317689
[TBL] [Abstract][Full Text] [Related]
8. An immunomodulating dipeptide, SCV-07, is a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
Rose WA; Tuthill C; Pyles RB
Int J Antimicrob Agents; 2008 Sep; 32(3):262-6. PubMed ID: 18619817
[TBL] [Abstract][Full Text] [Related]
9. Introduction: Is viral shedding a surrogate marker for transmission of genital herpes?
Sacks SL; Griffiths PD; Corey L; Cohen C; Cunningham A; Dusheiko GM; Self S; Spruance S; Stanberry LR; Wald A; Whitley RJ
Antiviral Res; 2004 Aug; 63 Suppl 1():S3-9. PubMed ID: 15450380
[TBL] [Abstract][Full Text] [Related]
10. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
[TBL] [Abstract][Full Text] [Related]
11. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions.
Barnabas RV; Celum C
Curr HIV Res; 2012 Apr; 10(3):228-37. PubMed ID: 22384842
[TBL] [Abstract][Full Text] [Related]
12. Developments in STD/HIV interactions: the intertwining epidemics of HIV and HSV-2.
Reynolds SJ; Quinn TC
Infect Dis Clin North Am; 2005 Jun; 19(2):415-25. PubMed ID: 15963880
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex and HIV infections and preterm PROM.
Ehsanipoor RM; Major CA
Clin Obstet Gynecol; 2011 Jun; 54(2):330-6. PubMed ID: 21508703
[TBL] [Abstract][Full Text] [Related]
14. Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding.
McNicholl JM; Leelawiwat W; Whitehead S; Hanson DL; Evans-Strickfaden T; Cheng CY; Chonwattana W; Mueanpai F; Kittinunvorakoon C; Markowitz L; Dunne EF
Int J STD AIDS; 2017 Mar; 28(4):372-379. PubMed ID: 27179350
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in the management of herpes simplex virus infection in HIV-infected persons.
Bartlett JG
Clin Infect Dis; 2004 Nov; 39 Suppl 5():S237-9. PubMed ID: 15494894
[No Abstract] [Full Text] [Related]
16. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.
Mujugira A; Magaret AS; Celum C; Baeten JM; Lingappa JR; Morrow RA; Fife KH; Delany-Moretlwe S; de Bruyn G; Bukusi EA; Karita E; Kapiga S; Corey L; Wald A;
J Infect Dis; 2013 Nov; 208(9):1366-74. PubMed ID: 23901094
[TBL] [Abstract][Full Text] [Related]
17. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.
Watson-Jones D; Wald A; Celum C; Lingappa J; Weiss HA; Changalucha J; Baisley K; Tanton C; Hayes RJ; Marshak JO; Gladden RG; Koelle DM
J Clin Microbiol; 2010 Oct; 48(10):3496-503. PubMed ID: 20702659
[TBL] [Abstract][Full Text] [Related]
18. Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge.
Fernández-Romero JA; Abraham CJ; Rodriguez A; Kizima L; Jean-Pierre N; Menon R; Begay O; Seidor S; Ford BE; Gil PI; Peters J; Katz D; Robbiani M; Zydowsky TM
Antimicrob Agents Chemother; 2012 Jan; 56(1):358-68. PubMed ID: 22064530
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Moss JA; Malone AM; Smith TJ; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Vincent KL; Motamedi M; Friend DR; Clark MR; Baum MM
Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689
[TBL] [Abstract][Full Text] [Related]
20. HIV/AIDS. Prevention cocktails: combining tools to Stop HIV's spread.
Cohen J
Science; 2005 Aug; 309(5737):1002-5. PubMed ID: 16099959
[No Abstract] [Full Text] [Related]
[Next] [New Search]
